Business Wire13d
Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39 th Annual Meeting
"The clinical and translational data package being presented at SITC ... Chief Executive Officer of Nimbus. "The monotherapy activity we observed is particularly noteworthy, as many second ...
Business Wire28d
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Selective and Highly Efficacious WRN Inhibitor for the Treatment of MSI-H Tumors," Nimbus is presenting new data from preclinical assays and several tumor models that support the potential of the ...
Finanznachrichten27d
Nimbus Therapeutics, LLC: Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Selective and Highly Efficacious WRN Inhibitor for the Treatment of MSI-H Tumors," Nimbus is presenting new data from preclinical assays and several tumor models that support the potential of the ...